Literature DB >> 32484414

Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.

Ijin Joo1, So Yeon Kim1, Tae Wook Kang1, Young Kon Kim1, Beom Jin Park1, Yoon Jin Lee1, Joon-Il Choi1, Chang-Hee Lee1, Hee Sun Park1, Kyoungbun Lee1, Haeryoung Kim1, Eunsil Yu1, Hyo Jeong Kang1, Sang Yun Ha1, Joo Young Kim1, Soomin Ahn1, Eun Sun Jung1, Baek-Hui Kim1, Hye Seung Han1, Jeong Min Lee1.   

Abstract

Background Hepatobiliary phase (HBP) hypointense nodules without arterial phase hyperenhancement (APHE) at gadoxetic acid-enhanced MRI may indicate hepatocellular carcinoma (HCC) or nonmalignant cirrhosis-associated nodules. Purpose To assess the distribution of pathologic diagnoses of HBP hypointense nodules without APHE at gadoxetic acid-enhanced MRI and to evaluate clinical and imaging features in differentiating their histologic grades. Materials and Methods This retrospective multicenter study included pathologic analysis-confirmed HBP hypointense nodules without APHE (≤30 mm) in patients with chronic liver disease or cirrhosis screened between January 2008 and June 2016. Central pathologic review by 10 pathologists determined final histologic grades as progressed HCC, early HCC, high-grade dysplastic nodule (DN), and low-grade DN or regenerative nodule. Gadoxetic acid-enhanced MRI features were analyzed by three radiologists. Multivariable logistic regression analyses with elastic net regularization were performed to identify clinical and imaging features for differentiating histologic grades. Results There were 298 patients (mean age, 59 years ± 10; 226 men) with 334 nodules evaluated, and progressed HCCs were diagnosed in 44.0% (147 of 334), early HCCs in 20.4% (68 of 334), high-grade DNs in 27.5% (92 of 334), and low-grade DNs or regenerative nodules in 8.1% (27 of 334). Serum α-fetoprotein level 100 ng/mL or greater (odds ratio, 2.7; P = .01) and MRI features including well-defined margin (odds ratio, 5.5; P = .003), hypointensity at precontrast T1-weighted imaging (odds ratio, 3.2; P < .001), intermediate hyperintensity at T2-weighted imaging (odds ratio, 3.4; P < .001), and restricted diffusion (odds ratio, 1.9; P = .04) were independent predictors for progressed HCC at multivariable analysis. Conclusion In patients at high risk for hepatocellular carcinoma (HCC), hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI corresponded mainly to progressed HCCs, early HCCs, and high-grade dysplastic nodules. High α-fetoprotein level and some imaging features at MRI helped to differentiate progressed HCC from lower grade nodules. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Motosugi in this issue.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32484414     DOI: 10.1148/radiol.2020192275

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

1.  Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Sangwon Han; Chong Hyun Suh; Richard Kinh Gian Do; Jeong Min Lee
Journal:  Acad Radiol       Date:  2020-09-20       Impact factor: 5.482

Review 2.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

3.  Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis.

Authors:  Marianna Alunni-Fabbroni; Sabine Weber; Osman Öcal; Max Seidensticker; Julia Mayerle; Peter Malfertheiner; Jens Ricke
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

Review 4.  Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance.

Authors:  Hyo Jung Park; Nieun Seo; So Yeon Kim
Journal:  Korean J Radiol       Date:  2022-04-13       Impact factor: 7.109

Review 5.  Current Imaging Diagnosis of Hepatocellular Carcinoma.

Authors:  Evangelos Chartampilas; Vasileios Rafailidis; Vivian Georgopoulou; Georgios Kalarakis; Adam Hatzidakis; Panos Prassopoulos
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

6.  Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging.

Authors:  Yeun-Yoon Kim; Ji Hye Min; Jeong Ah Hwang; Woo Kyoung Jeong; Dong Hyun Sinn; Hyo Keun Lim
Journal:  Ultrasonography       Date:  2022-01-28

7.  Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging.

Authors:  Yidi Chen; Yun Qin; Yuanan Wu; Hong Wei; Yi Wei; Zhen Zhang; Ting Duan; Hanyu Jiang; Bin Song
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

Review 8.  HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.

Authors:  Sandeep Arora; Roberta Catania; Amir Borhani; Natally Horvat; Kathryn Fowler; Carla Harmath
Journal:  Abdom Radiol (NY)       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.